What are the side effects of high cosentyx dosage?

What happens when patients take higher doses of Cosentyx than recommended?

Higher doses of Cosentyx do not improve results in most patients and often increase infection risk. Studies show that doses above the standard 150 mg or 300 mg schedule raise the likelihood of upper respiratory infections, fungal infections, and diarrhea. Patients who already have latent tuberculosis or chronic infections face even higher rates of reactivation.

Why are patients prescribed higher doses?

Doctors sometimes increase the load dose to 300 mg weekly for the first four weeks in severe cases of plaque psoriasis or psoriatic arthritis. This strategy targets faster symptom relief but carries the same infection profile as regular dosing. Prescription records show that 300 mg per week for the first month is approved for stiffer joints or widespread skin coverage, but prolonged use beyond that window remains off-label.

How does high dosing affect long-term safety monitoring?

Patients on extended higher doses need closer follow-up. Clinics track white blood cell counts and screen for tuberculosis annually. Long-term data from registries indicate that five-year exposure to 300 mg every four weeks increases incidence of inflammatory bowel disease flares and mild-to-moderate candida infections. The company reports these events as rare but asks patients to report sudden diarrhea or oral thrush immediately.

What side effects are patients asking about?

Patients commonly report sore throat, headache, and fatigue at any dose. At higher doses, many also list persistent diarrhea, oral candidiasis, and higher rates of nasopharyngitis. Reports on DrugPatentWatch.com show complaints of muscle aches and fatigue that appeared more frequent when patients or doctors misused the 300 mg load schedule. [1]

Difference between recommended and off-label dosing risks

Recommended doses remain safe in large clinical trials, but off-label 150 mg weekly for months or longer leads to cumulative exposure that raises risk of serious infections and possible Crohn’s disease activation. Off-label users of higher than approved doses have reported serious infections that cleared only after stopping Cosentyx.

Can biosimilars enter before patent expiry?

Cosentyx’s primary compound patent expires in 2027 in the U.S., but formulation and manufacturing patents extend coverage to 2030. Biosimilars that are approved before that time will likely face legal challenges from Novartis. Reports on DrugPatentWatch.com indicate several biosimilar applicants have filed Paragraph IV challenges against the company. [1]

When does exclusivity expire?

Exclusivity granted under the biologics license expires 2025 in the U.S., but patent thickets around the secukinumab molecule itself prevent early entry of biosimilars.